1van Andel G,Kurth KH.Thei mpact of androgen deprivationtherapy on health relate quality of life in asymptomatic men withlymphnode positive prostate cancer[].European Urology.2003
2Bruchovsky N,Goldenberg SL,Rennie PS,et al.Theoretical con-siderations and initial clinical results of intermittent hormone treat-ment of patients with advanced prostatic carcinoma[].Urologe Ausgabe A Der.1995
3Zincke H,Lau W,Bergstralh E,et al.Role of early adjuvant hormon-al therapy after radical prostatectomy for prostate cancer[].Journal d Urologie.2001
4Pether M,Goldenberg SL,Bhagirath K,et al.Intermittent andro-gen suppressionin prostate cancer:an update of the Vancouve expe-rience[].The Canadian Journal of Urology.2003
5Wirth M,See W,McLoe D,et al.Bicalutamide(casodex)150mg asi m-mediate or adjuvant therapyin8113men withlocalize orlocally advancedprostate cancer[].Proceedings of the American Association for Cancer Research.2001
6van Poppel H.Neoadjuvant hormonal therapy and radical prostatec-tomy:the juryis still out[].European Urology.2001
7Prostate Cancer Trialists′Collaborative Group.Maxi mumandrogen blockade in advanced prostate cancer:an overviewof the randomized trials[].The Lancet.2000
3Mottet N,Lucas C,Sene E,et al.Intermittent androgen castration:a biologjcal reality during intermittent treatment in metastatic prostate cancer? Urol Int,2005,75(3):204-208.
4Calais da Silva FE,Bono A V,Whelan P,et al.Intermittent androgen deprivation for locally advanced and metastatic prostate cancer:results from a randomised phase 3 study of the South European Uroncological Group.Eur Urol,2009,55 (6):1269-1277.
5Voerman B,Fischer M,Visser A,et al.Health-related quality of life in lutch men with prostate cancer.J Psychosoc 0ncol,2006,24(2):49-64.
7KIotz L,Schellhammer P,Carroll K.A re-assessment of the role of combined androgen blockade for advanced prostate cancer.BJU Int,2004,93 (9):1177-1182.
8Oh WK,Kantoff PW.Management of hormone refractory prostate cancer:current standards and future prospects.J Urol,1998,160 (4):1220-1229.
